eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes, was featured on the Grow Everything podcast discussing their innovative biomanufacturing platform. CEO Michael Heltzen highlighted how their exozymes technology enables sustainable chemical production outside living cells, offering advantages over traditional cell-based synthetic biology.
The company announced their first spinout, NCTx, which focuses on producing NCT, a rare small molecule with potential treatment applications for non-alcoholic fatty liver disease (NAFLD). eXoZymes is actively pursuing partnerships for co-development and licensing, with current projects including nutraceuticals, pharmaceuticals, and Sustainable Aviation Fuels backed by DoE and DoD funding.
eXoZymes (NASDAQ:EXOZ), un'azienda specializzata in enzimi progettati tramite intelligenza artificiale, è stata ospite del podcast Grow Everything per discutere della loro innovativa piattaforma di bioproduzione. Il CEO Michael Heltzen ha sottolineato come la loro tecnologia exozymes consenta una produzione chimica sostenibile al di fuori delle cellule viventi, offrendo vantaggi rispetto alla biologia sintetica tradizionale basata su cellule.
L'azienda ha annunciato la sua prima spin-off, NCTx, focalizzata sulla produzione di NCT, una piccola molecola rara con potenziali applicazioni terapeutiche per la steatosi epatica non alcolica (NAFLD). eXoZymes sta attivamente cercando partnership per lo sviluppo congiunto e la concessione di licenze, con progetti attuali che includono nutraceutici, farmaceutici e carburanti sostenibili per l'aviazione, supportati da finanziamenti del DoE e del DoD.
eXoZymes (NASDAQ:EXOZ), una empresa especializada en enzimas diseñadas mediante inteligencia artificial, fue destacada en el podcast Grow Everything para hablar sobre su innovadora plataforma de biomanufactura. El CEO Michael Heltzen destacó cómo su tecnología exozymes permite la producción química sostenible fuera de células vivas, ofreciendo ventajas sobre la biología sintética tradicional basada en células.
La compañía anunció su primera spin-off, NCTx, que se centra en la producción de NCT, una pequeña molécula rara con aplicaciones potenciales para el tratamiento de la enfermedad del hígado graso no alcohólico (NAFLD). eXoZymes está buscando activamente asociaciones para el co-desarrollo y licenciamiento, con proyectos actuales que incluyen nutracéuticos, productos farmacéuticos y combustibles sostenibles para la aviación, respaldados por financiamiento del DoE y DoD.
eXoZymes (NASDAQ:EXOZ)는 인공지능으로 설계된 효소를 전문으로 하는 회사로, Grow Everything 팟캐스트에 출연하여 혁신적인 생물제조 플랫폼에 대해 논의했습니다. CEO 마이클 헬첸은 exozymes 기술이 살아있는 세포 밖에서 지속 가능한 화학 생산을 가능하게 하여 전통적인 세포 기반 합성 생물학에 비해 이점을 제공한다고 강조했습니다.
회사는 첫 번째 스핀오프인 NCTx를 발표했는데, 이는 비알코올성 지방간 질환(NAFLD) 치료에 잠재적 응용이 있는 희귀 소분자 NCT 생산에 집중하고 있습니다. eXoZymes는 공동 개발과 라이선싱을 위한 파트너십을 적극적으로 모색 중이며, 현재 프로젝트에는 DoE 및 DoD 자금 지원을 받는 건강기능식품, 의약품, 지속 가능한 항공 연료가 포함되어 있습니다.
eXoZymes (NASDAQ:EXOZ), une entreprise spécialisée dans les enzymes conçues par intelligence artificielle, a été mise en avant dans le podcast Grow Everything pour discuter de leur plateforme innovante de bioproduction. Le PDG Michael Heltzen a souligné comment leur technologie exozymes permet une production chimique durable en dehors des cellules vivantes, offrant des avantages par rapport à la biologie synthétique traditionnelle basée sur les cellules.
L'entreprise a annoncé sa première filiale, NCTx, qui se concentre sur la production de NCT, une petite molécule rare avec des applications potentielles pour le traitement de la stéatose hépatique non alcoolique (NAFLD). eXoZymes recherche activement des partenariats pour le co-développement et la licence, avec des projets actuels incluant des nutraceutiques, des produits pharmaceutiques et des carburants d'aviation durables, soutenus par des financements du DoE et du DoD.
eXoZymes (NASDAQ:EXOZ), ein Unternehmen, das sich auf KI-entwickelte Enzyme spezialisiert hat, wurde im Grow Everything Podcast vorgestellt, um ihre innovative Bioproduktionsplattform zu diskutieren. CEO Michael Heltzen hob hervor, wie ihre Exozymes-Technologie eine nachhaltige chemische Produktion außerhalb lebender Zellen ermöglicht und Vorteile gegenüber traditioneller zellbasierter synthetischer Biologie bietet.
Das Unternehmen kündigte seine erste Ausgründung, NCTx, an, die sich auf die Produktion von NCT konzentriert, einem seltenen kleinen Molekül mit potenziellen Behandlungsmöglichkeiten für nicht-alkoholische Fettlebererkrankung (NAFLD). eXoZymes sucht aktiv Partnerschaften für gemeinsame Entwicklung und Lizenzierung, mit aktuellen Projekten in den Bereichen Nutraceuticals, Pharmazeutika und nachhaltige Flugkraftstoffe, die vom DoE und DoD gefördert werden.
- Launch of NCTx spinout company to produce NCT molecule for NAFLD treatment
- Technology enables scalable production of high-value compounds without cellular constraints
- Government backing through DoE and DoD funding for aviation fuel projects
- Recent successful NASDAQ listing indicating market confidence
- None.
Insights
eXoZymes' spinout NCTx represents significant commercial application of their AI-engineered enzyme platform for addressing unmet liver disease needs.
eXoZymes has made a strategic move by launching NCTx, a spinout company focused on producing NCT, a rare small molecule with potential therapeutic applications for non-alcoholic fatty liver disease (NAFLD). This development demonstrates the first major commercial application of their AI-engineered exozyme platform.
The key innovation here is their approach to biomanufacturing. Unlike traditional synthetic biology that struggles with cellular constraints, eXoZymes has developed enzymes that function outside of living cells, potentially solving the scaling challenges that have plagued many biotech companies. Their CEO, Michael Heltzen, correctly identifies that traditional cell-based manufacturing systems often face biological limitations that restrict industrial scalability.
From a market perspective, targeting NAFLD is strategically sound. This condition affects approximately 25% of the global population with limited treatment options currently available. If their NCT molecule proves effective, it could address a significant unmet medical need.
Their business strategy appears to focus on high-value, low-volume compounds in pharmaceuticals and nutraceuticals - a sensible approach for a platform technology that may still be optimizing its cost structure. The additional projects in Sustainable Aviation Fuels with Department of Energy and Department of Defense funding suggest potential diversification and government interest in their technology.
The podcast appearance with industry experts who highlighted the significance of overcoming scaling challenges indicates that eXoZymes' technology might represent a meaningful advance in biomanufacturing. This could potentially position them as an enabling technology provider in the growing synthetic biology space, which is projected to reach $30 billion by 2026.
MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - was featured on the latest episode of the Grow Everything podcast, revealing how the company's AI-engineered exozymes are reshaping the next generation of biomanufacturing by enabling sustainable chemical production outside of living cells.
Considered one of the leading podcasts in biotechnology, the Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder, M.S./M.F.A. Previous episodes have featured guests - including key individuals from companies like NVIDIA, Estée Lauder, and Robertet - discussing the impact of synthetic biology on all industries.
"Cells weren't built to manufacture what we need, and they fight us every step of the way. Using AI-engineered exozymes, we flip the model. We run enzyme-powered chemistry with engineering-level precision - without the constraints of biology. The right way to think of this, is really that exozymes is a new type of chemistry that doesn't deplete natural resources; it isn't toxic or polluting; and unlike cell-based SynBio, this does scale to an industrial level." states CEO of eXoZymes, Michael Heltzen.
Heltzen continues, "We just launched NCTx - our new spinout company producing NCT, a rare small molecule with strong potential to treat non-alcoholic fatty liver disease (NAFLD), which currently is an unmet nutritional and medical need. It's a perfect showcase for our platform: a powerful molecule found in nature, virtually impossible to access at scale - until now. In other words, we're not just prototyping anymore. We're building real solutions at scale - and we're inviting partners to join us."
Grow Everything podcast co-host, Erum Azeez Khan, comments, "Over the past decade, the move from the lab success to commercial scale has been a challenge for most synthetic biology projects. Overcoming that bottleneck makes engineered biology tangible, scalable, and investable. The NCTx announcement is a fundamental shift that makes biomanufacturing predictable and signals the industry has entered the next phase in biomanufacturing."
The entire podcast episode is available here on Apple Podcasts, Spotify, and YouTube.
Together with partners, eXoZymes' main focus is to scale production of high-value / low-volume compounds in the nutraceutical and pharmaceutical markets, as well as pursuing advanced projects like Sustainable Aviation Fuels, backed by DoE and DoD funding. The company recently went public on NASDAQ and is actively seeking partners for co-development and licensing.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to replace traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
SOURCE: eXoZymes
View the original press release on ACCESS Newswire
FAQ
What is eXoZymes' (EXOZ) main technology and how does it differ from traditional synthetic biology?
What is NCTx and what is its significance for EXOZ stock?
What markets is eXoZymes (EXOZ) targeting with their technology?
What are the key partnerships and funding sources for eXoZymes (EXOZ)?
